2.24
0.07 (3.23%)
| Previous Close | 2.17 |
| Open | 2.21 |
| Volume | 696,107 |
| Avg. Volume (3M) | 631,569 |
| Market Cap | 164,939,264 |
| Price / Earnings (Forward) | 8.00 |
| Price / Sales | 3.76 |
| Price / Book | 4.48 |
| 52 Weeks Range | |
| Earnings Date | 17 Mar 2025 |
| Profit Margin | 5.49% |
| Operating Margin (TTM) | 39.57% |
| Diluted EPS (TTM) | 0.040 |
| Quarterly Revenue Growth (YOY) | 73.70% |
| Total Debt/Equity (MRQ) | 12.79% |
| Current Ratio (MRQ) | 2.35 |
| Operating Cash Flow (TTM) | 8.67 M |
| Levered Free Cash Flow (TTM) | 5.43 M |
| Return on Assets (TTM) | 3.10% |
| Return on Equity (TTM) | 7.64% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Mixed |
| Biotechnology (Global) | Bearish | Mixed | |
| Stock | Protalix BioTherapeutics, Inc. | - | - |
AIStockmoo Score
| Analyst Consensus | -2.0 |
| Insider Activity | NA |
| Price Volatility | -1.5 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | 2.0 |
| Average | -0.13 |
|
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. It also develops PRX-102, a therapeutic protein candidate for the treatment of Fabry disease; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is based in Hackensack, New Jersey. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 13.70% |
| % Held by Institutions | 5.98% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Point72 Asia (Singapore) Pte. Ltd. | 30 Sep 2024 | 47,073 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 24 Mar 2025 | Announcement | Protalix BioTherapeutics to Present at the iAccess Alpha Virtual Best Ideas Spring Conference 2025 |
| 17 Mar 2025 | Announcement | Protalix BioTherapeutics Reports Fiscal Year 2024 Financial and Business Results |
| 10 Mar 2025 | Announcement | Protalix BioTherapeutics to Announce Fiscal Year 2024 Financial and Business Results on March 17, 2025 |
| 04 Feb 2025 | Announcement | Protalix BioTherapeutics to Participate in the 2025 BIO CEO & Investor Conference |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |